CoChat
Sign Up
Cited by 273

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice

Santos, Alexandra F., Alpan, Oral, Hoffmann, Hans‐Jürgen·2021·Allergy
DOI 10.1111/all.14747

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The basophil activation test (BAT) is a functional assay that measures the degree of degranulation following stimulation with allergen or controls by flow cytometry. It correlates directly with histamine release. From the dose‐response curve resulting from BAT in allergic patients, basophil reactivity (%CD63 + basophils) and basophil sensitivity (EC 50 or similar) are the main outcomes of the test. BAT takes into account all characteristics of IgE and allergen and thus can be more specific than sensitization tests in the diagnosis of allergic disease. BAT reduces the need for in vivo procedures, such as intradermal tests and allergen challenges, which can cause allergic reactions of unpredictable severity. As it closely reflects the patients' phenotype in most cases, it may be used to support the diagnosis of food, venom and drug allergies and chronic urticaria, to monitor the natural resolution of food allergies and to predict and monitor clinical the response to immunomodulatory treatments, such as allergen‐specific immunotherapy and biologicals. Clinical application of BAT requires analytical validation, clinical validation, standardization of procedures and quality assurance to ensure reproducibility and reliability of results. Currently, efforts are ongoing to establish a platform that could be used by laboratories in Europe and in the USA for quality assurance and certification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.14747

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC · From the PDF
FIGURE 1 Historical timeline of the basophil activation test (BAT). EQA, external quality assurance
FIGURE 1 Historical timeline of the basophil activation test (BAT). EQA, external quality assuranceCC-BY-NC · From the PDF
FIGURE 2 Examples of gating strategies for basophils: (a), Basophils were identified as SSClow CD123c + CD193 + cells 45,48 : 1. Lymphocyte -­ monocyte gate on a FSC/SSC plot using a logarithmic scale, 2. Doublet exclusion FSC-­ H vs. FSC-­ A, then SSC-­ H vs. SSC-­ H, 3. Gate on both markers simultaneously CD123 and CD193, 4. CD63 negative threshold was set to 2.5% and the positive population above that threshold was assessed. (b), Basophils were identified as Lymphocyte/monocyte gate, SSClow CD203c + CD123 + HLA- ­DR- ­. 2,6,26,37 The CD63 gate is set on the negative control and basophil activation is measured above this gate for the other stimulation conditions, either with allergen or positive controls
FIGURE 2 Examples of gating strategies for basophils: (a), Basophils were identified as SSClow CD123c + CD193 + cells 45,48 : 1. Lymphocyte -­ monocyte gate on a FSC/SSC plot using a logarithmic scale, 2. Doublet exclusion FSC-­ H vs. FSC-­ A, then SSC-­ H vs. SSC-­ H, 3. Gate on both markers simultaneously CD123 and CD193, 4. CD63 negative threshold was set to 2.5% and the positive population above that threshold was assessed. (b), Basophils were identified as Lymphocyte/monocyte gate, SSClow CD203c + CD123 + HLA- ­DR- ­. 2,6,26,37 The CD63 gate is set on the negative control and basophil activation is measured above this gate for the other stimulation conditions, either with allergen or positive controlsCC-BY-NC · From the PDF
FIGURE 3 A typical dose-­ response curve of basophil activation with increasing concentrations of allergen of a grass pollen allergic patient from a published study 45,48 is represented. The maximal basophil activation expressed is a measure of basophil reactivity. EC 50 is the concentration eliciting the half-­ maximal basophil activation and is a measure of basophil sensitivity
FIGURE 3 A typical dose-­ response curve of basophil activation with increasing concentrations of allergen of a grass pollen allergic patient from a published study 45,48 is represented. The maximal basophil activation expressed is a measure of basophil reactivity. EC 50 is the concentration eliciting the half-­ maximal basophil activation and is a measure of basophil sensitivityCC-BY-NC · From the PDF
Image 5
CC-BY-NC · From the PDF
FIGURE 5 Proposed sequence of tests to support the diagnosis of food allergy, before referring patient for an oral food challenge. CRD, component-­ resolved diagnosis; BAT, basophil activation test; MAT, mast cell activation test
FIGURE 5 Proposed sequence of tests to support the diagnosis of food allergy, before referring patient for an oral food challenge. CRD, component-­ resolved diagnosis; BAT, basophil activation test; MAT, mast cell activation testCC-BY-NC · From the PDF
Image 7
CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 116

  1. 10.1016/j.jaci.2014.04.039 · DOI
  2. 10.1111/all.14206 · DOI
  3. 10.1111/j.1398-9995.2010.02431.x · DOI
  4. 10.1111/all.12698 · DOI
  5. 10.1186/s13601-016-0100-4 · DOI
  6. 10.1016/S0091-6749(97)70033-2 · DOI
  7. 10.1371/journal.pone.0012204 · DOI
  8. 10.1038/sj.cr.7290301 · DOI
  9. Smiljkovic M, 2017, Apigenin‐7‐O‐glucoside versus apigenin: insight into the modes of anticandidal and cytotoxic actions, EXCLI J, 16, 795
  10. 10.1159/000328756 · DOI
  11. 10.3389/fimmu.2018.01644 · DOI
  12. 10.1080/20013078.2019.1650458 · DOI
  13. 10.1016/j.jim.2011.09.003 · DOI
  14. 10.1111/j.1365-2222.2010.03572.x · DOI
  15. 10.1016/j.cellsig.2009.03.018 · DOI
  16. 10.1042/BST20170450 · DOI
  17. 10.1002/eji.200737634 · DOI
  18. 10.1155/2019/9542656 · DOI
  19. 10.1111/j.1398-9995.2010.02460.x · DOI
  20. 10.1016/j.jaip.2018.09.034 · DOI
  21. 10.1186/1476-7961-6-12 · DOI
  22. 10.1016/j.jaci.2005.11.016 · DOI
  23. 10.1111/all.12952 · DOI
  24. 10.1016/j.jaci.2020.03.035 · DOI
  25. 10.1016/j.jaci.2013.06.038 · DOI
  26. 10.1111/cea.12155 · DOI
  27. 10.1111/j.1365-2222.2012.04013.x · DOI
  28. 10.4049/jimmunol.0801782 · DOI
  29. 10.1016/S0091-6749(06)80015-1 · DOI
  30. Kwok M, 2017, Improved standardisation of the whole blood basophil activation test to peanut, Clin Transl Allergy, 8, 15
  31. 10.1016/j.jaci.2016.04.060 · DOI
  32. 10.1111/j.1398-9995.2009.02004.x · DOI
  33. Pascal M, 2020, Building confidence in the basophil activation test: standardization and external quality assurance ‐ an EAACI task force, Allergy, 75, 115
  34. 10.1002/cyto.b.21537 · DOI
  35. 10.1016/j.jaci.2014.09.001 · DOI
  36. 10.1111/j.1398-9995.2004.00624.x · DOI
  37. 10.1111/j.1398-9995.2005.00870.x · DOI
  38. 10.1111/j.1365-2222.2011.03763.x · DOI
  39. 10.1111/j.1398-9995.2011.02754.x · DOI
  40. 10.1159/000350923 · DOI
  41. 10.1111/j.1398-9995.2008.01900.x · DOI · Paper page
  42. 10.1111/j.1398-9995.2005.00894.x · DOI
  43. 10.1111/j.1365-2222.2010.03524.x · DOI
  44. 10.1111/all.14264 · DOI
  45. 10.1111/j.1398-9995.2006.00987.x · DOI · Paper page
  46. 10.1111/j.1398-9995.2007.01476.x · DOI
  47. 10.1111/j.1398-9995.2009.02144.x · DOI
  48. 10.1111/j.1399-3038.2011.01260.x · DOI
  49. 10.1111/cea.12515 · DOI
  50. 10.1111/j.1365-2222.2011.03838.x · DOI · Paper page
  51. 10.1111/all.12581 · DOI · Paper page
  52. 10.1111/j.1365-2249.2011.04503.x · DOI
  53. 10.1016/0091-6749(93)90266-I · DOI
  54. 10.1016/j.jaci.2006.09.040 · DOI
  55. 10.1189/jlb.1208724 · DOI
  56. 10.1111/cea.12964 · DOI
  57. 10.1007/s11882-018-0831-5 · DOI
  58. Santos AF, 2019, Identifying allergic children with severe adverse events during oral peanut challenges in the LEAP studies by assessing basophil activation, Allergy, 74, 73
  59. 10.1186/s13601-016-0098-7 · DOI
  60. 10.1016/j.jaci.2012.02.008 · DOI
  61. 10.1111/all.13949 · DOI
  62. 10.1016/j.jaci.2008.12.1128 · DOI
  63. 10.1016/j.jaci.2018.01.044 · DOI
  64. 10.1016/j.anai.2015.01.006 · DOI
  65. 10.1111/j.1398-9995.2010.02432.x · DOI
  66. 10.1016/j.anai.2018.04.020 · DOI
  67. 10.1111/cea.13078 · DOI
  68. 10.1111/all.13135 · DOI
  69. 10.1111/all.13368 · DOI
  70. 10.1016/j.jaci.2019.09.005 · DOI
  71. 10.1016/j.jaci.2019.07.028 · DOI
  72. 10.1016/j.jaci.2015.01.012 · DOI
  73. McKendry RT, 2019, Basophil and mast cell responses to food allergens in sensitised but tolerant patients are not mediated via the FcgRII and FcgRII receptors, Allergy, 74, 97
  74. 10.1056/NEJMoa1200435 · DOI
  75. 10.1016/j.jaci.2013.11.007 · DOI
  76. 10.1016/j.jaci.2014.09.049 · DOI
  77. 10.1111/j.1365-2222.2012.04028.x · DOI
  78. 10.1016/j.jaci.2014.11.010 · DOI
  79. 10.1016/j.jaci.2016.12.965 · DOI
  80. 10.1016/j.jaci.2012.05.038 · DOI
  81. 10.1159/000260086 · DOI
  82. 10.1111/cea.13469 · DOI
  83. 10.1016/j.jaci.2012.05.039 · DOI
  84. 10.1016/j.jaci.2013.04.056 · DOI
  85. 10.1016/j.jaci.2009.09.012 · DOI
  86. 10.1111/j.1398-9995.2009.02051.x · DOI
  87. 10.1016/j.jaci.2011.07.021 · DOI
  88. 10.1111/cea.13066 · DOI
  89. 10.1016/j.jaip.2016.12.004 · DOI
  90. 10.1111/all.13319 · DOI
  91. 10.1111/myc.13081 · DOI
  92. 10.1016/j.jcf.2016.02.004 · DOI
  93. 10.1002/cyto.a.23078 · DOI
  94. 10.1586/1744666X.2014.959498 · DOI
  95. 10.1002/cyto.b.21532 · DOI
  96. 10.1002/cyto.b.21104 · DOI
  97. 10.1002/cyto.b.21105 · DOI
  98. 10.1002/cyto.b.21107 · DOI
  99. Pascal M, 2020, Building confidence in the basophil activation test: standardization and external quality assurance ‐ an EAACI task force, Allergy, 75, 115
  100. 10.1016/j.jaip.2016.12.003 · DOI
  101. 10.1111/all.12939 · DOI · Paper page
  102. 10.1016/j.jaci.2019.10.038 · DOI
  103. 10.1016/j.jaci.2018.03.011 · DOI
  104. 10.1016/j.jaci.2019.09.005 · DOI
  105. 10.1159/000094495 · DOI
  106. 10.1159/000115885 · DOI
  107. 10.1007/s40629-016-0005-8 · DOI
  108. 10.1111/j.1365-2222.2009.03292.x · DOI
  109. 10.1111/j.1365-2222.2009.03426.x · DOI
  110. 10.1111/j.1365-2044.2011.06729.x · DOI
  111. 10.1111/j.1398-9995.2004.00400.x · DOI
  112. 10.1183/13993003.01068-2015 · DOI
  113. 10.1016/j.jaci.2016.12.989 · DOI
  114. 10.1111/j.1398-9995.2006.01094.x · DOI
  115. Hansen MR, 2014, Occupational asthma caused by maleic anhydride, Ugeskr Laeger, 176, V04140237
  116. 10.1111/cea.12600 · DOI · Paper page

Cited by

Sorted by citations

See all 273

Metadata

Authors
Santos, A. F., Alpan, O., & Hoffmann, H.
Affiliations
  • Department of Women and Children's Health (Pediatric Allergy) School of Life Course Sciences Faculty of Life Sciences and Medicine King's College London London UK
  • Amerimmune Fairfax VA USA
  • Department of Clinical Medicine Aarhus University Aarhus Denmark
ORCID
Venue
Allergy
Publisher
Wiley
Published
2021-02-27
Volume
76
Issue
8
Pages
2420-2432
ISSN
  • 0105-4538
  • 1398-9995
DOI
10.1111/all.14747
Cited by
273
References
4
Language
en
Licence
creativecommons.org/licenses/by-nc/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice. https://app.cochat.ai/papers/10.1111/all.14747
The paper
Santos, A. F., Alpan, O., & Hoffmann, H. (2021). Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice. Allergy. https://doi.org/10.1111/all.14747